Epitalon
Epitalon overview

Epitalon

Injectionrecommended

Primary telomerase activation

First effectsWeek 1-2
Full benefitsMonth 3+

The most studied route for Epitalon with 30+ years of clinical use in Russia. Injection delivers the peptide systemically for telomerase activation, melatonin regulation, and anti-aging gene expression. Five protocols ranging from evidence-based microgram dosing to traditional Western milligram protocols.

Injection protocols

ProtocolDoseFrequency
Evidence-based (recommended)200-500mcgDaily
Conservative start100mcgDaily
Russian clinical equivalent300mcgDaily
Traditional Western (anecdotal)5-10mgDaily
Ultra-low dose50mcgDaily

Protocols are from published research literature. This is not medical advice. Dosing should be determined by a licensed clinician.

What to expect

Week 1-2

Enhanced morning energy, improved mood stability.

Week 2-4

Skin quality improvements, better wound healing.

Month 1-2

Measurable improvements in sleep quality via melatonin enhancement.

Month 3+

Cumulative telomerase activation and anti-aging benefits.

What to know

  • Generally well-tolerated with minimal side effects in studies
  • Corrected microgram dosing reduces risk of unnecessary peptide exposure
  • Theoretical concern about telomerase activation in cancer. Avoid if you have active cancer.
  • May cause mild injection site reactions
  • Some users report vivid dreams due to melatonin enhancement
  • No severe adverse events reported in 30+ years of Russian clinical use
  • Current Western protocols may represent significant overdosing

Other ways to take Epitalon

How Epitalon works

Activates telomerase enzyme at extremely low concentrations (10⁻¹⁷ to 10⁻¹⁵ M) to maintain telomere length, stimulates pineal gland for melatonin production, modulates gene expression through epigenetic mechanisms, and enhances antioxidant enzyme systems.

Key research

Al-Dulaimi S et al. · Biogerontology · 2025
Khavinson VKh et al. · Bulletin of Experimental Biology and Medicine · 2003
Khavinson V et al. · Neuroendocrinology Letters · 2002
Khavinson VKh et al. · Advances in Gerontology · 2002